ⅠB2、ⅡA2期宫颈癌术前新辅助化疗与腔内放疗对比研究  

Comparative Study on Preoperative Neoadjuvant Chemotherapy and Intracavitary Radiotherapy inⅠB2,ⅡA2 Stage Cervical Cancer

作　　者：许少榆[1] 吴素芳[1] 江少如[1] 邓林浩 王继宇[1] 

机构地区：[1]广东省揭阳市人民医院,广东揭阳522000

出　　处：《中国医学创新》2017年第14期43-46,共4页Medical Innovation of China

基　　金：广东省揭阳市医学科学技术研究立项(2016023)

摘　　要：目的:对比分析术前新辅助化疗与腔内放疗在ⅠB2、ⅡA2期宫颈癌治疗中的应用价值。方法:选取2009年2月-2013年12月本院收治的ⅠB2、ⅡA2期宫颈癌患者60例,将其随机分为两组,每组30例。两组均给予广泛性子宫切除术与盆腔淋巴清扫术,其中对照组术前采用腔内放疗,观察组予以术前新辅助化疗。比较两组肿瘤缩小情况、手术情况、复发率、生存率及不良反应发生率。结果:观察组肿瘤缩小总有效率为83.33%,与对照组的60.00%相比明显增加,差异有统计学意义(P<0.05);观察组手术时间与术中出血量分别为(176.28±24.42)min、(98.54±16.85)mL,均明显少于对照组的(198.15±32.56)min、(126.82±23.71)mL,差异均有统计学意义(P<0.05);观察组术后1、3年生存率分别为93.33%、83.33%,均明显高于对照组的73.33%、60.00%,差异均有统计学意义(P<0.05);观察组与对照组复发率、并发症发生率及不良反应发生率相比,差异均无统计学意义(P>0.05)。结论:术前新辅助化疗治疗ⅠB2、ⅡA2期宫颈癌较腔内放疗更有助于促进肿瘤缩小,改善近期疗效,提高患者生存率,应用价值更为明显。Objective： To compare and analyze the application value of preoperative neoadjuvant chemotherapy and intracavitary radiotherapy in treatment of ⅠB2, ⅡA2 stage cervical cancer.Method： From February 2009 to December 2013, 60 patients withⅠ B2,ⅡA2 stage cervical cancer admitted into our hospital were selected and divided into control group and observation group according to the random number table method, 30 cases in each group.Both two groups were given radical hysterectomy and pelvic lymphadenectomy, the control group took preoperative intracavitary radiotherapy and the observation group took preoperative neoadjuvant chemotherapy. The tumor regression situation, surgical situation, recurrence rate, survival rate and incidence of adverse reactions of two groups were compared.Result： The total effective rate of tumor regression of the observation group （ 83.33% ） was higher than that of the control group （ 60.00% ）, the difference was statistic significant （ P〈0.05 ） .The surgery time and intraoperative bleeding volume of the observation group were （ 176.28 ± 24.42 ） min and （ 98.54 ± 16.85 ）mL, which were better than the control group＇s （ 198.15 ± 32.56 ）min and （ 126.82 ± 23.71 ） mL, the differences were statistic significant （P〈0.05） .The postoperative survival rate of the observation group for 1 year and 3 years were 93.33% and 83.33% respectively, which were significantly higher than the control group＇s 73.33% and 60.00% （ P〈0.05 ） .The recurrence rate, incidence rate of complications and incidence rate of adverse actions of two groups were no statistical differences （ P〉0.05 ） .Conclusion： Preoperative neoadjuvant chemotherapy treating for Ⅰ B2, ⅡA2 stage cervical cancer can facilitate tumor regression, improve the short-term efficacy, increase the survival rate, which has application value

关 键 词：宫颈癌 新辅助化疗 腔内放疗 

分 类 号：R737.33[医药卫生—肿瘤]